Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.
Tridek-One has raised $16.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2022.
Tridek-One's investors include Bpifrance, Pureos Bioventures, AdBio partners, Advent Life Sciences, Bioqube Ventures.
Tridek-One is headquartered in Évry, France.
Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.
Tridek-One is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tridek-One — Funding & Investors." VCBacked, September 15, 2022, https://www.vcbacked.co/company/tridek-one. Accessed August 14, 2026.
VCBacked. (2022). Tridek-One — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tridek-one
{{cite web |title=Tridek-One — Funding & Investors |url=https://www.vcbacked.co/company/tridek-one |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated